UCB, a global biopharmaceutical company, today presented positive efficacy and safety results from the GEMZ phase 3 study investigating adjunctive fenfluramine in children and adults with CDKL5 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback